Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC
Status:
Completed
Trial end date:
2019-03-13
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability
of switching abacavir/lamivudine (ABC/3TC) fixed-dose combination (FDC) tablets to
emtricitabine/tenofovir alafenamide (F/TAF) FDC tablets versus maintaining ABC/3TC in human
immunodeficiency virus type 1 (HIV-1) infected adults who are virologically suppressed on
regimens containing ABC/3TC.